带有N-苯基马来酰亚胺的2-(1'-环烯基)噻吩和2-(1'-环烯基)苯并[ b ]噻吩的Diels-Alder / Ene反应性:环烯环大小对苯并噻吩和二苯并噻吩产物分布的作用
摘要:
噻吩和苯并噻吩的支架是自然界中发现的丰富的生物活性化合物的重要类别。2-(1'-环烯基)噻吩和2-(1'-环烯基)苯并[ b ]噻吩的Diels-Alder反应具有在五个,六个,七个,八个和十二个烷基中存在的烯基N取代的成员环-苯基马来酰亚胺被表征。环烯环的大小在决定预期的和异构化的Diels-Alder加合物的产物分布中起着至关重要的作用。2D NMR研究表明,具有五,六和七元环的2-(1'-环烯基)噻吩的分离的异构体是芳构化的苯并噻吩产物,而八和十二元环是未重排的加合物。另外,对于五元和六元环的情况,分离出随后的与N-苯基马来酰亚胺的烯反应的产物。有趣的是,在2-(1'-环烯基)苯并[ b具有五元,六元,七元,八元和十二元环的]噻吩,在任何情况下均未分离未重排的二苯并噻吩Diels-Alder加合物。进行分子力学和密度泛函理论(M06-2X和PBE0-D3)的计算是为了了解各种二烯对于
带有N-苯基马来酰亚胺的2-(1'-环烯基)噻吩和2-(1'-环烯基)苯并[ b ]噻吩的Diels-Alder / Ene反应性:环烯环大小对苯并噻吩和二苯并噻吩产物分布的作用
摘要:
噻吩和苯并噻吩的支架是自然界中发现的丰富的生物活性化合物的重要类别。2-(1'-环烯基)噻吩和2-(1'-环烯基)苯并[ b ]噻吩的Diels-Alder反应具有在五个,六个,七个,八个和十二个烷基中存在的烯基N取代的成员环-苯基马来酰亚胺被表征。环烯环的大小在决定预期的和异构化的Diels-Alder加合物的产物分布中起着至关重要的作用。2D NMR研究表明,具有五,六和七元环的2-(1'-环烯基)噻吩的分离的异构体是芳构化的苯并噻吩产物,而八和十二元环是未重排的加合物。另外,对于五元和六元环的情况,分离出随后的与N-苯基马来酰亚胺的烯反应的产物。有趣的是,在2-(1'-环烯基)苯并[ b具有五元,六元,七元,八元和十二元环的]噻吩,在任何情况下均未分离未重排的二苯并噻吩Diels-Alder加合物。进行分子力学和密度泛函理论(M06-2X和PBE0-D3)的计算是为了了解各种二烯对于
A novel synthesis of calix[4]thiophenes and calix[4]furans
作者:Gon-Ann Lee、Wen-Chieh Wang、Minghuey Shieh、Ting-Shen Kuo
DOI:10.1039/c0cc00437e
日期:——
The addition of heteroaryllithium to various ketones followed by dehydration gave 1-(2-heteroaryl)cycloalkenes and (2-hetero- aryl)alkenes. When alkenes were treated with 10 mol% NIS, calix[4]thiophenes and calix[4]furans were obtained in good yields.
The design of a novel series of muscarinic receptor antagonists leading to AZD8683, a potential inhaled treatment for COPD
作者:Antonio Mete、Keith Bowers、Richard J. Bull、Helen Coope、David K. Donald、Katherine J. Escott、Rhonan Ford、Ken Grime、Andrew Mather、Nicholas C. Ray、Vince Russell
DOI:10.1016/j.bmcl.2013.09.092
日期:2013.12
A novel series of muscarinic receptor antagonists was developed, with the aim of identifying a compound with high M-3 receptor potency and a reduced risk of dose-limiting side effects with potential for the treatment of COPD.Initial compound modifications led to a novel cycloheptyl series, which was improved by focusing on a quinuclidine sub-series. A wide range of N-substituents was evaluated to determine the optimal substituent providing a high M-3 receptor potency, high intrinsic clearance and high human plasma protein binding. Compounds achieving in vitro study criteria were selected for in vivo evaluation. Pharmacokinetic half-lives, inhibition of bronchoconstriction and duration of action, as well as systemic side effects, induced by the compounds were assessed in guinea-pig models.Compounds with a long duration of action and good therapeutic index were identified and AZD8683 was selected for progression to the clinic. (C) 2013 Elsevier Ltd. All rights reserved.
Modified Phenolic Resin, Epoxy Resin Composition Containing the Same, and Prepreg Containing the Composition
申请人:Abe Takaharu
公开号:US20080044667A1
公开(公告)日:2008-02-21
The modified phenolic resin of the present invention has a specific structure in which a side chain of an aromatic ring having a hydroxyl group in a phenolic resin that is an alternate copolymer of a phenolic compound and a compound having a divalent connecting group, is substituted with a group represented by general formula (1-1). By using the modified phenolic resin as a hardener for epoxy resins, there are provided an epoxy resin, a composition thereof, and a cured product thereof having excellent adhesion and flame retardancy without impairing properties of conventional phenolic resins such as gel time, glass transition temperature, moisture absorption, and mechanical properties.
(In the formula, R
1
represents a C
1-8
linear, branched, or cyclic hydrocarbon group.)
The present invention provides an epoxy resin composition with excellent adhesion and flame retardancy in uses such as hardeners for semiconductor sealing epoxy resins, insulating materials for electrical/electronic components, and laminates (printed circuit boards). A prepreg containing a glass substrate impregnated with the epoxy resin composition, a laminate, and an electronic circuit board are also provided.